Loyal vs ConcertAI
Side-by-side comparison of AI visibility scores, market position, and capabilities
Loyal is a veterinary biotech developing FDA-regulated longevity drugs for dogs; its lead drug LOY-001 received FDA reasonable expectation of effectiveness — the first longevity drug for any species to do so; raised $45M; founded by Celine Halioua.
About
Loyal is a veterinary biotechnology company founded in 2020 by Celine Halioua and headquartered in San Francisco, California. The company is developing pharmaceutical treatments designed to extend the healthspan and lifespan of dogs — large breeds in particular, which age faster and live shorter lives than small breeds. Loyal's approach is grounded in the biology of aging: targeting the hormonal, metabolic, and cellular mechanisms that drive age-related decline in dogs, with the goal of creating FDA-approved drugs that add healthy years to companion animals' lives.
ConcertAI is an oncology AI and real-world data company at a $1.9B valuation — 5.5M multi-modal cancer RWD records, $230M+ raised, exiting FY2024 profitable with mid-teens EBITDA margins.
About
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates multi-modal patient data — including electronic health records, genomics, imaging, and pathology — from a network of oncology providers to support biopharma companies in clinical trial design, site selection, protocol optimization, patient matching, and regulatory submission.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.